anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In one human study, patients with AIDS or advanced ARC who received AZT had fewer life-threatening infections, improved in weight and performance, and lived longer than patients who received a placebo (inactive medication). Further studies are needed because toxic effects associated with the use of AZT were noted and the long-term effectiveness and toxicity of AZT are still unknown. It is also unknown if AZT will benefit patients with less severe HIV infections such as early ARC or PGL.

Patients accepted into the study are randomly assigned to receive either AZT or placebo. Treatment continues for a minimum of 104 weeks beyond the time the last patient enters the study. If the study medication causes toxic effects, the dose is decreased or temporarily stopped, and if the toxic effects are severe, then the medication will be stopped permanently. Participants visit the clinic every 2 weeks during the first 16 weeks and once a month thereafter. Throughout the study frequent blood samples are taken to monitor the effectiveness and safety of the treatment. AMENDED: The placebo arm has been discontinued as of August 3, 1989 and the AZT dose has been reduced.
In this group, adolescents with major depressive disorder will be recruited. It was planned to include 30 participants.Escitalopram treatment will be given to those with Major Depressive Disorder with a starting dose of 2.5 mg day. The treatment dose will be gradually increased up to 20 mg day (if necessary) and the maximal treatment dose was determined as 30 mg day in each group.
Pseudomonas syringae pv. actinidiae biovar 3 (Psa3) causes a devastating canker disease in yellow-fleshed kiwifruit (Actinidia chinensis). The effector HopZ5, which is present in all isolates of Psa3 causing global outbreaks of pandemic kiwifruit canker disease, triggers immunity in Nicotiana benthamiana and is not recognised in susceptible A. chinensis cultivars. In a search for N. benthamiana nonhost resistance genes against HopZ5, we found that the nucleotide-binding leucine-rich repeat receptor NbPTR1 recognised HopZ5. RPM1-interacting protein 4 orthologues from N. benthamiana and A. chinensis formed a complex with NbPTR1 and HopZ5 activity was able to disrupt this interaction. No functional orthologues of NbPTR1 were found in A. chinensis. NbPTR1 transformed into Psa3-susceptible A. chinensis var. chinensis 'Hort16A' plants introduced HopZ5-specific resistance against Psa3. Altogether, this study suggested that expressing NbPTR1 in Psa3-susceptible kiwifruit is a viable approach to acquiring resistance to Psa3 and it provides valuable information for engineering resistance in otherwise susceptible kiwifruit genotypes.
First 2 weeks this group will be on a waiting list (day 1 to day 14). Then participants will receive transcutaneous vagal nerve stimulation 4hours a day (day 15 to day 28). Laboratory testing will be carried out three times with average of 14 days between sessions: on day 1 (waiting), on day 14 (pre-intervention) and on day 28 (post-intervention).
Inappropriate energy supply, may cause important complications that affect the progression of the disease, especially in critically ill patients receiving mechanical ventilation. Mechanically ventilated patients make a considerable respiratory muscle effort that is not always decreased by intermittent positive pressure ventilation.

No work of breathing is observed in patients under controlled mechanical ventilation who are receiving drugs for sedation and muscle paralysis. In this situation, the work of breathing is carried out by the ventilator which initiates the ventilation cycle, and patients are spared the inspiratory efforts. Conversely, in assisted ventilation modes, the patient has to make a considerable inspiratory effort before a ventilation cycle initiates, and there is no airflow up to the moment when the effective sensitivity threshold is reached by the ventilator. Therefore, the choice of ventilation mode may determine differences in energy expenditure.

Some studies found that in patients on mechanical ventilation, weight, height, body temperature, type of mechanical ventilation, and type of medication received influenced the REE Acute hypoxemic respiratory failure is a common reason for patients to be admitted to the intensive care unit (ICU). An international study showed an incidence of acute respiratory distress syndrome (ARDS) of 10.4% in ICU critically ill trauma patients with an hospital mortality reaching 46.1% for most severe cases. A protective ventilation strategy using low tidal vol-ume (LTV) and a plateau pressure lower than 30 cmH2O is widely accepted to limit ventilator-induced lung injury, and it currently represents the intervention able to reduce mortality supported by the strongest evidences. Airway pressure release ventilation (APRV) was described for the first time by Stock and Downs and consists in a time-triggered, pressure-limited and time-cycled ventilation mode in which the pressure was alternated from a high level (Phigh) applied for a prolonged time (Thigh) to maintain adequate lung volume and alveo-lar recruitment, to a low level (Plow) for a short period of time (Tlow) where most of ventilation and CO2 removal occurs. In contrast to pressure-controlled inverse-ratio ventilation, APRV uses a release valve that allows spontaneous breathing during any phase of respiratory cycle. The rationale behind this approach is to maintain a pressure above the closing pressure of recruitable alveoli for a sustained time, limiting the release time to allow CO2 removal but avoiding de-recruitment. Another conceptual advantage to APRV over controlled modes is the preservation of spontaneous breathing, which may pro-mote a redistribution of aeration to the dependent lung regions, less need for neuromuscular blockade and sedation, improved venous return and a better ventilation/perfusion (V/Q) matching. For this reason, APRV has been considered a tempting mode of ventilation during acute respiratory failure within the concept of open lung ventilation.
Disclosed herein is a biomaterial for treating a condition. A biomaterial of the disclosure can be, for example, a surgical article. The biomaterial can comprise a plurality of geometric elements and a therapeutic agent. The biomaterial can comprise a first geometric element formed by a porous border that comprises a polymer and the therapeutic agent. The biomaterial can comprise a second geometric element formed by a non-porous border and a solid region, wherein the therapeutic agent may not diffuse into the second geometric element. Implantation of a biomaterial disclosed herein into a subject can treat, for example, cancer.
PROBLEM TO BE SOLVED: To obtain colored flaky glass suitable for use as a colorant ensuring no irregular color, having satisfactory extensibility and excellent in transparency and tough and to obtain a high quality decorative material contg. the flaky glass. SOLUTION: This colored flaky glass contains 0.1-50wt.% fine grains of titanium oxide of lower order, titanium oxynitride or titanium nitride. It is produced preferably by heating flaky glass contg. dispersed fine titanium dioxide grains having 1-30nm grain diameter or a precursor of the flaky glass under reducing conditions optionally in the presence of a nitrogen compd. so that the fine titanium dioxide grains are converted into fine grains of titanium oxide of lower order, titanium oxynitride or titanium nitride.
A method of suppressing microbial virulence. The method includes administering and/or applying a composition. The composition includes (a) a surfactant comprising (i) a polyethylene glycol compound comprising a fatty acid moiety, or (ii) a fatty acid containing compound. The composition further includes (b) (i) a phosphate containing compound, and (ii) a metal salt; and (c) an aqueous carrier. The surfactant is present in an amount of between 0.01 wt. % and 1 wt. %, based on the total weight of the composition.
The relationship between sarcopenia and the long-term risk of atrial fibrillation (AF) remains unclear. This study recruited a large prospective Caucasian cohort from the UK Biobank. Participants were assessed at baseline with handgrip strength and muscle mass and were categorized into groups of non-sarcopenia, probable sarcopenia, and confirmed sarcopenia. Kaplan-Meier method and Cox proportional hazards model were used to explore the association between sarcopenia and the incidence of AF. The genetic predisposition of AF was assessed by polygenic risk score. Sensitivity analyses were performed to validate the results. A total of 384,433 participants with a median age of 58 years and 54.3% women were enrolled in this study. There were 24,007 cases of new-onset AF over a median follow-up of 12.56 years. The groups of non-sarcopenia, probable sarcopenia, and confirmed sarcopenia accounted for 22,290 (6.1%), 1665 (9.2%), and 52 (11.9%) cases, respectively. Compared with the non-sarcopenia group, participants with probable sarcopenia or confirmed sarcopenia had an 8% (95% CI, 1.03-1.14) or 61% (95% CI, 1.23-2.12) higher risk of AF incidence. The findings remained robust in multiple sensitivity analyses, such as subgroup analysis and further adjustment of genetic predisposition. Notably, the association between sarcopenia and a high AF risk was more pronounced in younger participants, women, and those with valvular heart disease. In conclusion, sarcopenia was associated with a high long-term risk of AF in Caucasians, supporting sarcopenia as a new independent risk factor of AF.
Each participant in this arm will outline a small number of activity-related goals and will receive a 4 month personalised physical programme where additional physical activity will be incorporated into their daily routines. Nursing home staff will receive two educational sessions, which will provide them with the necessary skills to monitor participants physical activity programmes within the nursing home.
The present invention relates to a multilayered blood product and also to methods for preparing the blood product. The blood product comprises components from whole blood: fibrin, thrombocytes and leukocytes. The blood product comprises three layers, wherein the second layer is adjacent to the first layer and to the third layer, the first layer defines a first outer surface of the blood product, and the third layer defines a second outer surface of the blood product. The first layer comprises a majority of fibrin, the second layer comprises a majority of thrombocytes and the third layer comprises a majority of leukocytes. The blood product may be obtainable by methods using a container means, the inner surface of which is made from a material activating or not activating coagulation process. The volume of whole blood is placed in a container means, coagulation of the whole blood is activated, then the coagulated whole blood is separated into erythrocytes, serum and blood product by a centrifugal force being at least 1000 g acting on the whole blood for at least 30 sec, and the obtained blood product is removed from the container means.
The present invention relates to novel vectors, to DNA vaccines and gene therapeutics containing said vectors, to methods for the preparation of the vectors and DNA vaccines and gene therapeutics containing the vectors, and to therapeutic uses of said vectors. More specifically, the present invention relates to novel vectors comprising (a) an expression cassette of a gene of a nuclear-anchoring protein, which contains (i) a DNA binding domain capable of binding to a specific DNA sequence and (ii) a functional domain capable of binding to a nuclear component and (b) a multimerized DNA sequence forming a binding site for the anchoring protein, and optionally (c) one or more expression cassettes of a DNA sequence of interest. In particular the invention relates to vectors that lack a papilloma virus origin of replication. The nuclear-anchoring protein might be the E2 protein of Bovine Papilloma Virus type 1 or Epstein-Barr Virus Nuclear Antigen 1. The invention also relates to vectors that lack an origin of replication functional in a mammalian cell. The invention further relates to methods for expressing a DNA sequence of interest in a subject.
The invention discloses a recombinant fusion protein of streptococcus equi subspecies 8 proteins, a preparation method and application thereof. The recombinant fusion protein is obtained by connecting cne, eag, sclC, sclI, sclF, eq, eq8 and ideE 8 proteins of streptococcus equi Ma Yachong sequentially through protein linkers Gly-Gly-Gly. Preferably, the recombinant fusion protein is named as SE8, and the amino acid sequence of the recombinant fusion protein is shown as SEQ ID NO. 2. Experiments prove that the recombinant fusion protein SE8 prepared by the invention has good antigenicity and immunogenicity, and immunized mice can effectively induce organisms to generate high-level specific antibodies, and can play a role in protecting S.equi infected mice. In addition, the recombinant fusion protein is a bacterial protein prepared by purifying escherichia coli, does not contain other components, has higher safety, and avoids the phenomenon of infection morbidity.
BACKGROUND: Heart failure (HF) is a clinical syndrome that seriously endangers human health and quality of life as the terminal stage of cardiovascular diseases. Ferroptosis as a new iron-dependent programmed cell death mode that is closely related to the occurrence and development of cardiovascular diseases. Dihydroorotate dehydrogenase (DHODH) has been found to play a crucial role in inhibiting ferroptosis and improving mitochondrial function, and its expression can be upregulated by estradiol (E2). Recent studies have found that DHODH can inhibit ferroptosis by reducing coenzyme Q (CoQ) to CoQH2. Therefore, this study aims to explore the effect of up-regulation of DHODH on the pathological hypertrophy and fibrosis of heart failure and its mechanisms.
METHODS: The mouse heart failure model was established by transverse aortic constriction (TAC), surgery in mice. Two days after the operation, a subcutaneous injection of E2 or the same volume of sesame oil was given for 8 weeks. Then, the left ventricular systolic function related indicators of mice were measured by echocardiography, and the degree of myocardial fibrosis of mice was detected by histological analysis; the expression levels of heart failure markers were detected by quantitative polymerase chain reaction (q-PCR) and western blot (WB) analysis; the morphological changes of mitochondria in cardiac cells of mice were observed by transmission electron microscopy. Cell model were established by stimulating with phenylephrine for 96 hours. Ferroptosis markers were detected by kits and WB analysis. Mitochondrial function was verified by a JC-1 fluorescent probe, and 2',7'-Dichlorodihydrofluorescein diacetate (DCFH-DA) staining. The knockdown results were detected by WB analysis after transfection of small interfering RNA (siRNA) of CoQ. Fer-1 was added as a positive control to verify the ferroptosis-related changes of myocardial cells.
RESULTS: In the animal model, we found that E2 treatment alleviates TAC-induced cardiac hypertrophy and fibrosis and suppresses cardiomyocyte ferroptosis by promotes DHODH upregulation in murine cardiomyocytes. In the cell model, DHODH upregulation protects against phenylephrine-induced cardiomyocytes with failure. However, the effect on up-regulating DHODH was inhibited by transfection to down-regulate CoQ expression.
CONCLUSIONS: The up-regulation of DHODH could effectively ameliorate the manifestations of heart failure such as myocardial hypertrophy and fibrosis in mice after TAC surgery, inhibit ferroptosis of cardiac myocytes, and ameliorate mitochondrial function. The mechanism involves CoQ-related biological processes.
PURPOSE: Shift-working nurses must function against their natural circadian system and are, thus, bound to be detrimentally affected by social jetlag. Circadian rhythms play a crucial role in regulating homeostasis, and social jetlag may increase one's risk for obesity. Therefore, this study aimed to identify associations between social jetlag and obesity among shift-working nurses.
METHODS: This cross-sectional study included 183 nurses working rotating shifts in South Korea. Chronotype and social jetlag were measured using the Morningness-Eveningness Questionnaire and the Munich Chronotype Questionnaire for Shift-Workers, respectively. Obesity was defined as a body mass index of 25.0 or higher, which was calculated using self-reported height and weight data. The associations between chronotype, social jetlag, and obesity were investigated using multiple logistic regression analysis.
FINDINGS: A total of 183 nurses were included in the analysis (81.4% women and 80.3% single, median age = 27.00 years). Majority of the participants' (95.1%) chronotypes were moderate evening or intermediate type. The mean overall social jetlag was 3 h and 31 min. The odds for obesity were 8.44 times higher among shift-working nurses whose social jetlag was over 3 h and 31 min (95% confidence interval: 1.66-42.99) while controlling for chronotype, exercise time, and eating habits.
CONCLUSIONS: Social jetlag may increase the likelihood of obesity among rotating shift-working nurses.
IMPLICATIONS FOR NURSING PRACTICE: To achieve positive outcomes for promoting nurses' health, upper nursing management should consider individual nurses' social jetlag when scheduling shifts. In addition, nursing managers should have the responsibility to educate nurses involved in shift work about the adverse effects of social jetlag.
The invention relates to a compound medicinal composition for treating avian infectious bronchitis and a preparation method thereof. The compound medicinal composition comprises the following raw material medicaments in part by weight: honeysuckle flower 12-50, purple perilla 4-9, divaricate saposhnikovia root 4.5-9, common achyranthes herb 9-15, indigowoad leaf 4-9, arrowshaped tinospora root 5-9, Spergula maxima 9-15, dandelion 9-30 and astragalus 9-30. The compound medicinal composition comprises the following steps:1, weighing by amount; 2, rinsing and drying; 3, crushing and screening; 4, immersing and extracting; 5, pressing and permeating extraction; 6, flocculating settling; 7, filtering and impurity removal; and 8, concentration and pure water addition. The active ingredients of the medicament have functions of relieving a cough and resisting viruses, can effectively treat chicken cough, sneeze, respiratory inflammation and the like and has a function of restoring the egg yield of poultry. Meanwhile, the compound medicinal composition also has sterilizing and bacteriostatic functions and thus relieves respiratory inflammation. The compound medicinal composition can effectively improve the immunity of the bodies of poultry.
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition and application thereof. The traditional Chinese medicine composition comprises the following components in parts by weight: 170 portions of clove 150-. The components of the composition of the invention all adopt natural traditional Chinese medicine raw materials, and the composition has simple and convenient preparation, wide medicine sources and low cost. The pungent and warm herbs are the main ones. Pungent-warm property enters meridians to dispel cold, unblock meridians to alleviate pain, and induce various herbs to enter interior and expel pathogenic factors to reach exterior. Has the advantages of convenient application, low cost and treatment of both symptoms and root causes.
"• Context: Oral anticoagulation is recommended for prevention of stroke and thrombo-embolic events in people aged 80 years and over (octo+) suffering from non valvular atrial fibrillation (nv AF) and without contraindication to anticoagulant therapy. Two drug classes are available to achieve this oral anticoagulation: the vitamin K antagonists (VKA, warfarin, fluinione and acenocoumarol) or the Direct Oral Anticoagulants (DOAC, dabigatran, rivaroxaban and apixaban). The data of evidence-based and post-marketing literature on the benefit/risk ratio of DOAC comparatively to VKA are limited, conflicting, potentially biased and finally inconclusive in this population. Nevertheless, this population is the most at risk for nv AF and the population with the highest risk of both AF-related thrombotic events and anticoagulant-related major bleedings.

* Objectives: The aim of the study is to assess and compare the real benefits and harms of the two therapeutic strategies available in routine practice, for the anticoagulation in patients 75 years old or more suffering from nvAF. The main objective is to estimate and compare DOAC and VKA in terms of major bleeding, thrombotic events (TE) and death of all cause in 75 years old or more suffering from nv AF. The secondary objectives are to identify factors associated with the occurrence of these events, taking into account the type of anticoagulant, to identify factors associated with the occurrence of these events, taking into account switches from VKA to DOAC or DOAC to VKA, and to describe the utilization patterns of oral anticoagulants.
* Design and statistical analyses: An observational study will be conducted in the French administrative database (SNIIRAM). The SNIIRAM database contains anonymous and prospectively recorded data about all beneficiaries' medical reimbursements including age, gender, long-term chronic disease (LTD), date of death, all out-hospital health-spending reimbursements and all patients' hospitalizations. We will include all octo+ patients they care for, newly treated ("new users") with an oral anticoagulant (VKA or DOAC) for nv AF, at the date of first prescription of oral anticoagulant. From the date, patients data will be collected during at least 2 years. To assess the principal endpoint, we will estimate the time between the date of inclusion and the date of occurrence of a major thromboembolic event, major bleeding event, or death from any cause, whichever comes first. Exposure will be considered as time-dependant. The total number of patients expected is 150 000."
The invention relates to the technical field of disinfectant, in particular to a nano silver ion disinfectant as well as a preparation method and application thereof. The nano silver ion disinfectant comprises water, nano titanium dioxide, a nano silver ion solution, a nano gold dispersion solution and a functional auxiliary agent. The nano silver ion disinfectant can be used as a disinfectant and a wound auxiliary material, water is used as a carrier, the composite water-based nano titanium dioxide and nano silver ions are used as antibacterial components, and the nano gold dispersion liquid plays a catalytic role in the formula. The disinfectant not only has the performance of the conventional disinfectant, but also can be used as a wound auxiliary material and can effectively kill viruses; can also be used as a sterilizing disinfectant and an antistaling agent for fresh foods, fruits and vegetables. The preparation method of the nano silver ion disinfectant has simple steps and is suitable for industrial mass production. The nano silver ion disinfectant has wide application range, can be suitable for skin disinfection, object disinfection and space air purification disinfection, can be directly used as stock solution, and can also be used for soaking, smearing and spraying after being diluted.
After completion of the Phase I portion of the study, new participants will be enrolled for the randomized, placebo-controlled Phase II. Participants randomized in this group will receive placebo for Tadalafil, the Anti-MUC1 Vaccine and the Anti-Influenza Vaccine for 5 courses. A standard of care (SOC) tumor removal surgery will be completed after the completion of Course 1. Course 2 will resume 5-8 weeks after completion of SOC tumor removal surgery.